Interview Summary OK 6/8/2006

REMARKS

The present amendment is filed in response to the Office Action dated August 29, 2005. Claims 1-10, 14-26, 28, 31-44, 46-61 are now present in this case. Claims 1, 20, and 49-51 have been amended. New claims 56-61 have been added, and these claims find support throughout the application as filed, including for example page 6, lines 5-10 ("*the invention describes parsing of a population into selected phenotypic groups...*" including ARA and ARU; page 30, line 9 to page 32, line 28 (section beginning "*Individual Subject Analysis and Classification*" and continuing through the paragraph beginning, "*The patients are segregated into three phenotypic classifications...*").

The applicants wish to express their appreciation to the Examiner and the Examiner's supervisor for the personal interview with the applicants and the applicants' attorney on December 5, 2005. The technology developed by the applicants was discussed generally with the Examiner. In addition, the references of record in the case were discussed with the Examiner and distinctions between the cited references and the claimed invention discussed.

Applicants acknowledge receipt of the written Interview Summary in which the substance of the interview was indicated to be a discussion of the differences between the "super healthy" and the ARU population; identifying a drug target using candidate gene screening; and NIH risk analysis methods being a future predictive method. These issues are addressed herein, in the context of the issues raised in the Office Action.

Claims 1-10, 14-26, 28, 31-44, and 46-55 stand rejected under 35 U.S.C. § 112, first paragraph as allegedly failing to comply with the written description requirement. The applicants respectfully traverse this rejection and request reconsideration. For ease of identifying the language in the specification, applicants refer the Examiner to Table 1 below, which summarizes the language noted by the Examiner and the relevant claim, and the corresponding support in the specification.